Florent Ubelmann

Enthusiast: Life sciences I Biotech I DNA repair I Oncology I Alzheimer's I Intracellular trafficking

[PRV Watch @PRVWatch]

7 Priority Review Voucher sales announced so far this year with the smaller biotechs opting to monetize their PRVs as soon as possible from it being issued. Prices between $180M - $200M holding strong.

[Max Unfried @MaxUnfried]

The largest gathering in aging research comes to @Harvard!

It will be a program packed with pharma executives, academics, and biotechs!

A team effort by @biogerontology @ScheibyeKnudsen @Dr_Bischof @gladyshev_lab @InSilicoMeds

[Paras Sharma @paras_biotech]

Biotech IPO Cohorts: Capital, Time & Maturity
(2017-2026)

**Biotech IPOs have evolved from ~$80–100M, ~6-year, Phase 1 companies achieving ~1.5–2.0x re-ratings to ~$500M pvt raisings, ~11-year, Phase 2/3 companies accessing public markets with minimal valuation uplift

[Samuel Hume @DrSamuelBHume]

Who's targeting neuroinflammation in clinical trials?

[Nature Biotechnology @NatureBiotech]

Transposable elements, such as retrotransposons and endogenous retroviruses, are increasingly recognized for their important roles in genome function and impact on disease development. How can we translate our growing understanding of the 'dark genome' into therapeutics? https://t.co/ZTnidtAIgK
https://t.co/8bYPC6fVm1

[Adam Feuerstein ✡️ @adamfeuerstein]

Very strong $XENE Ph3 data, better than its previous Ph2 study.

[Waggoner Lab @LabWaggoner]

Phosphoenolpyruvate (PEP), a metabolite in glycolysis, directly inhibiting cyclic GMP–AMP synthase (cGAS). Biphasic fluctuation and eventual collapse of PEP levels during aging driving onset of inflammaging @NatureAging
https://t.co/S4BMxh9Ut4
https://t.co/FQwbUTkmZp 🇨🇳

[Eric Topol @EricTopol]

Our immune system is the driver of the biologic process of aging. A new and comprehensive review @NatRevImmunol
https://t.co/0Fm9w7U341

[Waggoner Lab @LabWaggoner]

TBK1 is a natural Asparagine sensor that links host nutritional homeostasis to antiviral immune responses
https://t.co/5mLB3p2pev @MolecularCell 🇨🇳

[Paras Sharma @paras_biotech]

VC Biotech Financing by therapeutic area

- $9.15B raised in 2H25 vs $8.9B in 1H25
- In 1H25, there were 32 deals $100M+ vs 36 in 2H25
- 4Q notably picked up mirroring public market sentiment
- ~2/3 of total $ invested were in clinical-stage companies

Source: Evercore

[Paras Sharma @paras_biotech]

Biotech is a lottery business: most drugs fail, a few wins pay for everything.

BridgeBio’s insight: manage biotech like a portfolio, not a single bet ($10M to IND & $25M IND to POC)

Source: https://t.co/8WpCVMfBbz

[Ohad Hammer @ohadhammer]

China biotech landscape update from Jefferies. Unprecedented level of activity and R&D productivity, only question is what the industry is going to do with so many interchangeable programs.

[Dr Jason Dungu PhD FRCP FESC @drjasondungu]

Promising early data for the novel myosin modulator EDG-7500 (catchy!) from CIRRUS HCM trial, presented by Anjali Owens and discussed by Iacopo Olivotto. Doesn’t affect LVEF so won’t need serial echo.
#HeartFailure2025

[Ohad Hammer @ohadhammer]

Great slide on efficacy IBD with the different classes from Guggenheim.
Placebo rates can be variable across studies but looks like new mechanisms can take remission rates from 10-15% (placebo adjusted) to 20-25% with novel agents. TL1A antiodies seem optimal in terms of eficacy and safety.
Key question is around combining two MOAs, currently being pursued with bispecifics and combination studies like $SYRE

[Leon Tang, Ph.D. @LeonTangBiotech]

@BiotechCH Licensing is NOT the largest source of capital for #ChinaBiotech. #HKEX biotech index has more than doubled in 2025.
Many IPOs completed or in planning for HKEX as well. More investor money will have flown to China than pharmas by YE 2025
https://t.co/6YA5SNiitq

[Nature Biotechnology @NatureBiotech]

Natural molecular glues spur next-gen small molecules for ‘undruggable’ targets https://t.co/zG3MBP3ACU
https://t.co/blLHlCrFvG

[Sleuth @sleuthinsights]

Get in touch to uncover white space opportunities and BD strategies for your pipeline programs

[PAIN Journal @PAINthejournal]

Broad et al. find that the TRPA1 antagonist LY3526318 inhibited behavioral signs of enhanced nociception in animal models and was safe and well tolerated in phase 1 clinical studies. Learn more in #PAIN https://t.co/m0DqC2L5nj

[Florent Ubelmann @florubel]

One potent gene raises risk of Alzheimer’s, Parkinson’s and other brain diseases https://t.co/LNVCG41qN6

[BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech]

1/ 🧬 How to Price a Platform in Biotech

Q2 M&A is ripping, Capstan just cleared $2.1B at Phase 1, and something important has changed.

A new market dynamic may be emerging, where optionality matters again.

Let’s break it down with math, comps, and a framework 🧵